Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: (2). Regulation of human IgE response.
The ability of IPD-1151T to suppress the induction of human IgE synthesis was investigated with an in vitro model of IgE production mediated by an allergen-specific helper T cell line (SN-4) from a patient allergic to Japanese cedar pollen. IPD-1151T induced a concentration-dependent suppression of purified allergen (Cry j 1)-dependent IgE synthesis in autologous B cell cultures mediated by SN-4, without significantly affecting the IgG synthesis. In addition, the production of interleukin 4 (IL-4) by Cry j 1-activated SN-4 as well as that by phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMC) of normal donors was inhibited in a concentration-dependent manner by the agent. Interestingly, IPD-1151T clearly depressed PHA-induced expression of IL-4 mRNA in normal PBMC, indicating that this agent inhibits IL-4 gene transcription. However, IPD-1151T had no antagonistic action on IL-4, since neither IL-4-induced expression of low-affinity IgE receptor (Fc epsilon RII/CD23) on normal B cells nor soluble Fc epsilon RII release from IL-4-stimulated B cells was affected by the agent. On the other hand, IPD-1151T had no effect on the production of interferon-gamma by both Cry j 1-stimulated SN-4 and anti-CD3 monoclonal antibody-activated T cells of normal donors. These results suggest that the selective suppression of IgE synthesis by IPD-1151T results from the inhibition of IL-4 production by T cells at the gene level.
Clinical Research Center for Allergy, National Sagamihara Hospital, Kanagawa, Japan.
Y
Y
Yanagihara
M
M
Kiniwa
K
K
Ikizawa
T
T
Shida
N
N
Matsuura
A
A
Koda
D000485:Allergens / Q000276:immunology; D001190:Arylsulfonates / Q000008:administration & dosage / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D015152:Blotting, Northern; D002460:Cell Line; D002478:Cells, Cultured; D006633:Histamine Antagonists / Q000494:pharmacology*; D006801:Humans; D007073:Immunoglobulin E / Q000096:biosynthesis*; D007371:Interferon-gamma / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis* / Q000276:immunology; D017455:Receptors, IgE / Q000096:biosynthesis; D011994:Recombinant Proteins / Q000276:immunology; D013452:Sulfonium Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects / Q000276:immunology*
D000485:Allergens; D001190:Arylsulfonates; D006633:Histamine Antagonists; D017455:Receptors, IgE; D011994:Recombinant Proteins; D013452:Sulfonium Compounds; D015847:Interleukin-4; D007073:Immunoglobulin E; D007371:Interferon-gamma; C073028:suplatast tosilate